Evidence map›Paper›PMID 24291098›Full record

ReviewEuropean journal of pharmacology2014

FK506-binding protein 1b/12.6: a key to aging-related hippocampal Ca2+ dysregulation?

J C Gant, E M Blalock, K-C Chen, I Kadish, N M Porter, C M Norris, O Thibault, P W Landfield

Open access · greenAbstract readReview
In one paragraph

Review in European journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. FK506-Binding Protein 12.6/1b, a Negative Regulator of [CaThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Emerging pathways driving early synaptic pathology in Alzheimer's disease.Biochemical and biophysical research communications · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

J C GantDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States.
E M BlalockDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States.
K-C ChenDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States.
I KadishDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States.
N M PorterDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States.
C M NorrisDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States.
O ThibaultDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States.
P W LandfieldDepartment of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose St., UKMC Lexington, KY 40536, United States. Electronic address: pwland@uky.edu.
University of Kentucky · US

Funding

HIPPOCAMPAL SYNAPTIC STRUCTURE--PHYSIOLOGY DURING AGINGR37AG004542 · NIA · UNIVERSITY OF KENTUCKY · PI LANDFIELD, PHILIP W. · 1998 to 2020
$7.1M
Calcineurin and inflammatory signaling processes in aging and Alzheimer's DiseaseR01AG027297 · NIA · UNIVERSITY OF KENTUCKY · PI NORRIS, CHRISTOPHER MARK · 2006 to 2018
$3.2M
HIPPOCAMPAL SYNAPTIC STUCTURE-PHYSIOLOGY DURING AGINGR01AG004542 · NIA · WAKE FOREST UNIVERSITY · PI LANDFIELD, PHILIP W. · 1985 to 1995
–
NIA NIH HHS AG004542NIA NIH HHS R01 AG027297NIA NIH HHS R37 AG004542
6 · The paper itself

Abstract

It has been recognized for some time that the Ca(2+)-dependent slow afterhyperpolarization (sAHP) is larger in hippocampal neurons of aged compared with young animals. In addition, extensive studies since have shown that other Ca(2+)-mediated electrophysiological responses are increased in hippocampus with aging, including Ca(2+) transients, L-type voltage-gated Ca(2+) channel activity, Ca(2+) spike duration and action potential accommodation. Elevated Ca(2+)-induced Ca(2+) release from ryanodine receptors (RyRs) appears to drive amplification of the Ca(2+) responses. Components of this Ca(2+) dysregulation phenotype correlate with deficits in cognitive function and plasticity, indicating they may play critical roles in aging-related impairment of brain function. However, the molecular mechanisms underlying aging-related Ca(2+) dysregulation are not well understood. FK506-binding proteins 1a and 1b (FKBP1a/1b, also known as FKBP12/12.6) are immunophilin proteins that bind the immunosuppressant drugs FK506 and rapamycin. In muscle cells, FKBP1a/1b also bind RyRs and inhibits Ca(2+)-induced Ca(2+) release, but it is not clear whether FKBPs act similarly in brain cells. Recently, we found that selectively disrupting hippocampal FKBP1b function in young rats, either by microinjecting adeno-associated viral vectors expressing siRNA, or by treatment with rapamycin, increases the sAHP and recapitulates much of the hippocampal Ca(2+) dysregulation phenotype. Moreover, in microarray studies, we found FKBP1b gene expression was downregulated in hippocampus of aging rats and early-stage Alzheimer's disease subjects. These results suggest the novel hypothesis that declining FKBP function is a key factor in aging-related Ca(2+) dysregulation in the brain and point to potential new therapeutic targets for counteracting unhealthy brain aging.

Indexed as

AgingAnimalsCalciumHippocampusHumansNeuronsTacrolimus Binding ProteinsCalciumtacrolimus binding protein 1BTacrolimus Binding ProteinsAgingCalciumFKBP1bRyanodine receptor

Identifiers

PMID24291098
PMCPMC4037392
OpenAlexW1966727159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.